Skip to main content
SpringerLink
Log in

Adjuvante Chemo-Immunotherapie beim malignen Melanom

  • Conference paper
Adjuvante zytostatische Chemotherapie

Part of the book series: Hämatologie und Bluttransfusion ((HAEMATOLOGY,volume 22))

  • 14 Accesses

Zusammenfassung

Damit eine adjuvante Behandlung irgendwelcher Art nach Lokalbehandlung eines malignen Tumors in Erwagung gezogen werden kann, müssen zwei grundsätzliche Voraussetzungen erfüllt sein:

  1. 1.

    Notorisch ungünstiger natürlicher Verlauf bei allen Patienten mit diesem Tumor oder in bestimmten, klar erkennbaren Risikogruppen, bzw. wahrscheinliche rasche Rezidive und/oder Fermetastasen ohne Zusatzbehandlung.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bast, R. C. et al., BCG and Cancer. New Engl. J. Med. 290, 1413–1420 und 1458–1469 (1974)

    PubMed  Google Scholar 

  2. Blume, M. R. et al., Comparison of BCG with transfer factor in adjuvant immunotherapy of stage III malignant melanoma. Proc. ASCO C-241 (1977)

    Google Scholar 

  3. Bluming, A. Z., Immunological effects of BCG in malignant melanoma: two modes of administration compared. Ann. intern. med. 76, 405–411 (1972)

    PubMed  CAS  Google Scholar 

  4. Borberg, H., Die BCG-Behandlung des malignen Melanoms. Internist 16, 483–485 (1975)

    Google Scholar 

  5. Bukowski, R. M. et al., The Transfer Factor therapy of stage II malignant melanoma. In „Adjuvant therapy of cancer<<, Amsterdam: Elsevier North Holland Pubi. p. 431–438. 1976

    Google Scholar 

  6. Cassel, W. A., Viral oncolysate in the management of malignant melanoma. Cancer 40, 672–679 und 680–686 (1977)

    Article  PubMed  Google Scholar 

  7. Clark, W. H., The developmental biology of primary human malignant melanomas. Semin. Oncol. 2, 83–103 (1975)

    PubMed  Google Scholar 

  8. Comis, R. L., DTIC in malignant melanoma: a perspective. Cancer Treat. Rep. 60, 165–176 (1976)

    PubMed  CAS  Google Scholar 

  9. Currie, G. A., Cancer and the immune response. London: Edward Arnold 1974

    Google Scholar 

  10. Currie, G. A., et al., Active Immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study. Br. J. Cancer 31, 143–156 (1977)

    Article  Google Scholar 

  11. DeVita, V. T., Fisher R. I., Natural history of malignant melanoma as related to therapy. Cancer Treat. Rep. 60, 153–157 (1976)

    Google Scholar 

  12. Dilawari, R. A. et al., Treatment of primary melanoma with intralesional BCG. Proc. ASCO 1191 (1975)

    Google Scholar 

  13. Eilber, F. R. et al., Adjuvant immunotherapy with BCG in treatment of regional-lymphnode metastases from malignant melanoma. New Engl. J. Med. 294, 237–240 (1976)

    Article  PubMed  CAS  Google Scholar 

  14. Eilber, F. R. et al., Results of BCG adjuvant immunotherapy for melanoma of the head and neck. Amer. J. Surg. 132, 476–479 (1976)

    Article  PubMed  CAS  Google Scholar 

  15. Einhorn, L. H. et al., Chemotherapy of disseminated malignant melanoma. Cancer Res. 34, 1995–2004 (1974)

    PubMed  CAS  Google Scholar 

  16. EI-Domeiri, A. A. et al., Adjuvant therapy of melanoma. Proc. AACR, 709 (1977)

    Google Scholar 

  17. Elwood, J. M., Lee J. A. H., Recent data on the epidemiology of malignant melanoma. Semin. Oncol. 2, 83–103 (1975)

    Google Scholar 

  18. Everall, J. D. et al., Treatment of primary melanoma with intralesional BCG before excision. Lancet 2, 583–586 (1975)

    Article  PubMed  CAS  Google Scholar 

  19. Everall J. D., Diagnosis, prognosis and treatment of melanoma. Lancet 2, 286–289 (1977)

    Article  PubMed  CAS  Google Scholar 

  20. Florentin, I., Experimental basis of BCC systemic immunotherapy. Cancer Immunol. Immunother. 1, 7–9 (1976)

    Google Scholar 

  21. Grant, R. M., Results of administering BCG to patients with melanoma. Lancet 2, 1096–1100 (1974)

    Article  PubMed  CAS  Google Scholar 

  22. Grooms, G. A., Morton D. L., Failure of adjuvant immunotherapy to prevent brain metastases in malignant melanoma. Proc. ASCO 1160 (1975)

    Google Scholar 

  23. Gutterman, J. U. et al., Active immunotherapy with BCG for recurrent malignant melanoma. Lancet 1, 1208–1212 (1973)

    Article  PubMed  CAS  Google Scholar 

  24. Gutterman, J. U. et al., Chemoimmunotherapy of disseminated malignant melanoma with DTIC and BCG. New Engl. J. Med. 291, 592–597 (1974)

    Article  PubMed  CAS  Google Scholar 

  25. Gutterman, J. U. et al., BCG Immunotherapy in combination with DTIC for the treatment of malignant melanoma. Cancer Treat. Rep. 60, 177–182 (1976)

    PubMed  CAS  Google Scholar 

  26. Gutterman, J. U. et al., An effective new chemo-immunotherapy regimen for disseminated malignant melanoma. Proc. ASCO C-135 (1977)

    Google Scholar 

  27. Hilal, E. Y. et al., Surgical adjuvant therapy of malignant melanoma with C. parvum. Proc. ASCO C-229 (1977)

    Google Scholar 

  28. Hill, G. J. et al., DTIC therapy for melanoma: correlation of toxicity with response and longevity in 742 patients. Proc. ASCO C-30 (1976)

    Google Scholar 

  29. Hill, G. J. et al., DTIC-melanoma adjuvant study. Final report. Proc. ASCO C—11 (1978)

    Google Scholar 

  30. Herrmann, W. P. et al., Rückbildung von Melanommetastasen nach Injektion von Freund’schem Adjuvans. Hautarzt 21, 181–183 (1970)

    PubMed  CAS  Google Scholar 

  31. Hunter-Craig, I. et al., Use of vaccinia virus in the treatment of metastatic malignant melanoma. Brit. med. J. 1, 512–515 (1970)

    Article  Google Scholar 

  32. Ishmael, D. R. et al., Results of treatment of surgically resected melanoma with immunotherapeutic agents BCG and C. parvum. Proc. ASCO C-309 (1977)

    Google Scholar 

  33. Jungi, W. F., BCG in der Krebstherapie — Wunschtraum oder Therapie der Zukunft? Schw. med. Wschr. 106, 1389–1391 (1976)

    CAS  Google Scholar 

  34. Jungi, W. F. et al., unveröffentlichte Ergebnisse

    Google Scholar 

  35. Khan, A. et al., Immunotherapy of metastatic melanoma with transfer factor, Proc. ASCO C-154 (1976)

    Google Scholar 

  36. Kleeberg, U. R., Die Behandlung des Melanoms. Dtsch. med. Wschr. 101, 904–908 (1976)

    Article  PubMed  CAS  Google Scholar 

  37. Krown, S. E. et al., Intralesional injection of MER in cutaneous malignant melanoma. Proc. ASCO C-300 (1977)

    Google Scholar 

  38. Lichtenfeld, J. L., Current concepts in the management of malignant melanoma. Amer. J. Med. Sci. 272, 184–195 (1976)

    Article  Google Scholar 

  39. Luce, J. K., Chemotherapy of melanoma. Semin. Oncol. 2, 179–185 (1975)

    PubMed  CAS  Google Scholar 

  40. Malek-Mansour, S., Immunotherapy of melanoma with DNCB. In „Adjuvant therapy of Cancer”, Amsterdam: Elsevier/North Holland 1976, p. 447–454

    Google Scholar 

  41. McIllmurray, M. B. et al., Controlled trial of active immunotherapy in management of stage II B malignant melanoma. Brit. med. J. 1, 540–542 (1977)

    Article  PubMed  CAS  Google Scholar 

  42. McMurtrey, M. J. et al., Adjuvant chemoimmunotherapy for stage III malignant melanoma. Proc. ASCO C-168 (1977)

    Google Scholar 

  43. McPherson, T. A. et al.,: a pilot study of adjuvant chemoimmuno-therapy. In „Adjuvant therapy of cancer”, Amsterdam: Elsevier/North Holland 1976, p. 439–446

    Google Scholar 

  44. Mitchell, M. S. et al., Effect of chemotherapy and immunotherapy on tumor-specific immunity in melanoma. J. Clin. Invest. 59, 1017–1026 (1977)

    Article  PubMed  CAS  Google Scholar 

  45. Minton, J. P., Mumps virus and BCGvaccine in metastatic melanoma. Arch. surg. 106, 503–506 (1973)

    PubMed  CAS  Google Scholar 

  46. Morton, D. L. et al., Adjuvant therapy in melanoma and sarcomas. In „Adjuvant therapy of cancer”, Elsevier/North Holland, Amsterdam 1976, p. 391–397

    Google Scholar 

  47. Morton, D. L. et al., Present status of BCG immunotherapy of malignant melanoma. Cancer Immunol. Immunother. 1, 93–98 (1976)

    Article  Google Scholar 

  48. Morton, D. L., Cancer Immunotherapy. An overview. Semin. Oncol. 1, 297 (1974)

    PubMed  CAS  Google Scholar 

  49. Nathanson, L., Regression of intradermal malignant melanoma after intralesional injection of BCG. Cancer Chemother. Rep. Vol. 1, 56, 659–665 (1972)

    Google Scholar 

  50. Nathanson, L. et al., A comparative study of 2 methods of administration of BCG in malignant melanoma. Proc. ASCO C-14 (1976)

    Google Scholar 

  51. Obrecht, J. P. et al., persönliche Mitteilung

    Google Scholar 

  52. Patt, Y. et al., Prognostic significance of initial immunological evaluation in stage 3B melanoma treated with thymosin, BCG and DTIC. Proc. ASCO C-72 (1977)

    Google Scholar 

  53. Perry, H. O., Winkelmann R. K., The experimental use of phenylalanine-mustard in the treatment of malignant melanomas. Acta derm.-venereol. 49, 564–568 (1969)

    PubMed  CAS  Google Scholar 

  54. Presant, C. A., Therapy of metastatic malignant melanoma with cyclophosphamide plus DTIC with or without C. parvum. Proc. ASCO C-68 (1977)

    Google Scholar 

  55. Pritchard, K. I., The use of oral BCG in the treatment of metastatic malignant melanoma. Med. Ped. Oncol. 2, 173–181 (1976)

    Article  CAS  Google Scholar 

  56. Richman, S. P. et al., Epilesional scarification. J. amer. med. ass. 234, 1233–1235 (1975)

    Article  CAS  Google Scholar 

  57. Saal, J. G. et al., Regional BCG-therapy of malignant melanoma: in vitro monitoring of spontaneous cytolytic activity of circulating lymphocytes. Cancer Immunol. Immunother. 2, (1977)

    Google Scholar 

  58. Salmon, S. E., Immunotherapy of cancer: present status of trials in man. Cancer Res. 37, 1245–1248 (1977)

    Google Scholar 

  59. Sears, H., Rosenberg S. A., Immune depression with BCG septicemia. Proc. ASCO C-245 (1977)

    Google Scholar 

  60. Seigler, H. F. et al., Non-specific and specific immunotherapy in patients with melanoma. Surgery 72, 162–174 (1975)

    Google Scholar 

  61. Serrou, B. et al., Improved clinical results of malignant melanoma with complementary chemo-immunotherapy. Proc. ASCO C-349 (1977)

    Google Scholar 

  62. Tritsch, H., Onkolyse bei Melanom-Lymphknotenmetastasen. Dtsch. med. Wschr. 95, 2432–2433 (1970)

    Article  PubMed  CAS  Google Scholar 

  63. Wright, P. W. et al., Immunotherapy with „unblocking” plasma in malignant melanoma: in vivo and in vitro correlates. Proc. ASCO, C-136 (1977)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung für Onkologie und Hämatologie, Medizinische Klinik C, Kantonsspital St. Gallen, Switzerland

    W. F. Jungi

Authors
  1. W. F. Jungi
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medizinische Universitätsklinik Innsbruck, Anichstraße, A-6020, Innsbruck, Austria

    Heinz Huber

  2. Medizinische Klinik C und Abteilung für Onkologie und Haematologie, Kantonsspital St. Gallen, CH-9007, St. Gallen, Switzerland

    Hansjörg Senn

  3. Inselspital, CH-3010, Bern, Switzerland

    Michael Falkensammer

Rights and permissions

Reprints and permissions

Copyright information

© 1978 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Jungi, W.F. (1978). Adjuvante Chemo-Immunotherapie beim malignen Melanom. In: Huber, H., Senn, H., Falkensammer, M. (eds) Adjuvante zytostatische Chemotherapie. Hämatologie und Bluttransfusion, vol 22. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-67111-1_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-67111-1_18

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-09069-4

  • Online ISBN: 978-3-642-67111-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation